Barclays Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $41

Barclays analyst Eliana Merle has maintained an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ: APLS) and raised the price target from $24 to $41. This adjustment reflects a positive outlook on the company's performance.